C4 Therapeutics, Inc.
CCCC
$2.61
-$0.21-7.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.57% | 16.55% | 98.56% | 71.44% | 65.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.57% | 16.55% | 98.56% | 71.44% | 65.45% |
| Cost of Revenue | 3.00% | 11.99% | 3.58% | -6.01% | -8.01% |
| Gross Profit | -9.11% | -10.22% | 17.30% | 22.59% | 23.33% |
| SG&A Expenses | -11.08% | -1.41% | -0.62% | 0.10% | -0.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.93% | 8.24% | 2.44% | -4.40% | -6.04% |
| Operating Income | -1.85% | -6.15% | 12.09% | 15.72% | 16.44% |
| Income Before Tax | -13.05% | -4.56% | 17.35% | 19.84% | 21.43% |
| Income Tax Expenses | -52.71% | -89.77% | -89.77% | -89.77% | -72.38% |
| Earnings from Continuing Operations | -12.88% | -3.44% | 18.08% | 20.51% | 21.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.88% | -3.44% | 18.08% | 20.51% | 21.81% |
| EBIT | -1.85% | -6.15% | 12.09% | 15.72% | 16.44% |
| EBITDA | -1.66% | -6.05% | 12.28% | 15.89% | 16.53% |
| EPS Basic | 1.95% | 16.71% | 37.95% | 43.20% | 38.03% |
| Normalized Basic EPS | 9.80% | 14.43% | 35.05% | 43.04% | 37.81% |
| EPS Diluted | 1.95% | 16.71% | 37.95% | 43.20% | 38.11% |
| Normalized Diluted EPS | 9.80% | 14.43% | 35.05% | 43.04% | 37.81% |
| Average Basic Shares Outstanding | 10.42% | 18.66% | 28.41% | 39.74% | 31.51% |
| Average Diluted Shares Outstanding | 10.42% | 18.66% | 28.41% | 39.74% | 31.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |